Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433300 | 0.82 | NPC1 (0.60) | NPC1RAB9ALMNAGLABRCA1 | |
| SCHEMBL7757826 | 0.81 | NPC1 (0.58) | NPC1RAB9ALMNAGLABRCA1 | |
| SCHEMBL422787 | 0.81 | RAB9A (0.62) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL395100 | 0.80 | NPC1 (0.54) | NPC1RAB9ALMNAGSK3BGLA | |
| SCHEMBL1531737 | 0.80 | MAPT (0.50) | NPC1RAB9ALMNAGSK3BGLA | |
| Methane SCHEMBL6835154 | 0.79 | RAB9A (0.60) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL14382566 | 0.79 | ALDH1A1 (0.63) | NPC1RAB9ALMNAGLABRCA1 | |
| SCHEMBL14799462 | 0.79 | NPC1 (0.71) | NPC1RAB9ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL9250225 | 0.78 | NPC1 (0.58) | NPC1RAB9ALMNAGLABRCA1 | |
| SCHEMBL6379829 | 0.78 | NPC1 (0.55) | NPC1RAB9ALMNAGLABRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3988544-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020253882-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | 中山大学中山眼科中心 | 2020-12-24 | — | — | WO | disclosed |
| CN-107964090-B | Copolymer containing chlorine-substituted thieno [3,4-b ] thiophene unit, preparation method thereof and polymer photovoltaic device | 南方科技大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-109952297-A | Compound | 奥斯陆大学 | 2019-06-28 | — | — | CN | disclosed |
| CN-106588644-B | A kind of synthetic method of carboxylic acid ester compound | 杭州师范大学 | 2019-03-29 | — | — | CN | disclosed |
| CN-106588644-A | Synthesis method of carboxylic ester compound | 杭州师范大学 | 2017-04-26 | — | — | CN | disclosed |
| EP-1402895-A1 | Benzimidazole inhibitors of fructose 1,6-biphosphatase | Metabasis Therapeutics, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0970095-B1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6399782-B1 | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6110903-A | INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE AT THE AMP SITE; ADMINISTERING TO TREAT DIABETES AND INHIBIT GLUCONEOGENESIS; 5-FLUORO-7-BROMO-1-ISOBUTYL-2-(2-PHOSPHONO-5-FURANYL) BENZIMIDAZOLE, FOR EXAMPLE | SANKYO COMPANY LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0970095-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039343-A9 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039343-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5354549-A | Iodinated esters | NYCOMED IMAGING AS (NO) | 1994-10-11 | — | — | US | disclosed |
| EP-0300828-B1 | IODINATED ESTERS | NYCOMED AS (NO) | 1992-03-18 | — | — | EP | disclosed |
| WO-1989000988-A1 | IODINATED ESTERS | NYCOMED AS (NO) | 1989-02-09 | — | — | WO | disclosed |
| EP-0300828-A1 | Iodinated esters | NYCOMED AS (NO) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | ROCK1, ROCK2, CIT | NPC1 2069/4885RAB9A 582/4885LMNA 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.